Gland Pharma has plunged under its essential help degree, which had held agency since October 2024, marking a brand new 52-week low. The breakdown from a chronic consolidation vary suggests intensified bearish stress.
The inventory is buying and selling considerably under its 20, 50, 100, and 200-day EMAs, highlighting sturdy downward momentum. RSI is at 24.34, deep in oversold territory, however this doesn’t rule out additional draw back.
The MACD is in bearish territory, with widening gaps between the sign and MACD strains, suggesting continued promoting stress.
Volumes have spiked on this breakdown, indicating sturdy participation by sellers. Buyers ought to keep away from lengthy positions for now. Quick help lies close to 1,500, whereas resistance is anticipated at 1,620.
